Business
Neurochem announces departure of two members of management team
LAVAL, QC, Feb. 21 /CNW Telbec/ - In light of Neurochem Inc.'s (NASDAQ: NRMX; TSX: NRM) new strat...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nLAVAL, QC, Feb. 21 /CNW Telbec/ - In light of Neurochem Inc.'s\n(NASDAQ: NRMX; TSX: NRM) new strategic direction, the Company announces the\ndeparture, effective February 21, 2008, of two members of its senior\nmanagement team, Dr. Andreas Orfanos, MBB. Ch, MBA, Executive Vice President,\nStrategic Planning and Scientific Affairs, and Ms. Christine Lennon, MBA, Vice\nPresident, Business Development. The possibility of their acting as\nconsultants in respect of specific projects is being explored.\n\n\n"On behalf of the Board of Directors and my colleagues, I want to express\nour gratitude to Dr. Orfanos and Ms. Lennon for their dedication and valuable\ncontribution to Neurochem. We wish them every success in the future," said\nDr. Francesco Bellini, Neurochem's Chairman, President and CEO.\n\n\nAbout Neurochem\n\n\nNeurochem Inc. is a global health company focused on the research,\ndevelopment and commercialization of products to provide innovative health\nsolutions to address critical unmet medical needs.\n\n\nTo Contact Neurochem\n\n\nFor additional information on Neurochem and its drug development\nprograms, please call the North American toll-free number 1-877-680-4500 or\nvisit our Web Site at www.neurochem.com.\n\n\nCertain statements contained in this news release, other than statements\nof fact that are independently verifiable at the date hereof, may constitute\nforward-looking statements. Such statements, based as they are on the current\nexpectations of management, inherently involve numerous risks and\nuncertainties, known and unknown, many of which are beyond Neurochem Inc.'s\ncontrol. Such risks include but are not limited to: the impact of general\neconomic conditions, general conditions in the pharmaceutical and/or\nnutraceutical industry, changes in the regulatory environment in the\njurisdictions in which the Neurochem group does business, stock market\nvolatility, fluctuations in costs, and changes to the competitive environment\ndue to consolidation, that actual results may vary once the final and\nquality-controlled verification of data and analyses has been completed, as\nwell as other risks disclosed in public filings of Neurochem Inc.\nConsequently, actual future results may differ materially from the anticipated\nresults expressed in the forward-looking statements. The reader should not...